科研队伍
研究员/高级工程师
助理研究员/工程师
研究助理/助理工程师
技术员/学生
联系我们

电话:0755-86392238

地址:深圳市南山区西丽大学城学苑大道1068号

研究员/高级工程师

您当前所在的位置:首页>>科研队伍>>研究员/高级工程师
王言

王言

副研究员、硕导

研究领域:药物筛选

邮箱:yan.wang@siat.ac.cn

  • 个人简介
  • 代表性项目
  • 代表性成果
  • 团队成员
  • 王言Wang, Yan,副研究员。主要研究计算机筛选药物的新方法和新型体外药物筛选平台的建立,结合这两种技术,开展了天然产物的活性筛选研究,以及现有药物的二次开发研究。建立了中药高丰度物质化合物库,并开发出第一个用于天然产物筛选的程序Herbalog,极大的提高了天然产物筛选效率。在药物筛选方法开发方面,建立了针对人源乙酰胆碱酯酶(AChE),淀粉样蛋白(β-amyloid)和脂肪酸结合蛋白4(FABP4)的体外高通量筛选模型,以及针对HIV integrase/p75CXCR4/SDF-1进行Protein-Protein Interaction抑制剂筛选的细胞模型。开发了首个针对HCMV terminase的抑制剂定量筛选方法,以及首个针对其的高通量筛选方法,获得NIH的认可,在此基础上资助200万美元开发HCMV terminase抑制剂。王言博士共开发药物筛选平台十余个,其中全新平台五个,为针对新靶点的药物设计和开发打下基础,其亦利用计算机筛选和体外筛选平台,进行药物二次开发研究。发现levofloxacinpimozide作为新的FABP4抑制剂,具有治疗代谢类疾病的潜质,该发明获得美国专利授权,多家海外公司和科研院所表达合作意向,被Nature Reviews Endocrinology等权威杂志引用。在药物筛选领域发表SCI文章35篇,其中以第一作者/通讯作者身份发表文章17篇。在新冠期间开展了抗新冠病毒的药物再评价研究,被评为2020年中科院抗疫亮点工作,并受邀在上海合作组织青年科学家论坛做大会报告。现为广东省自然科技基金药学/中药学方向评审专家,深圳市海外引进孔雀人才。


  • 1.         国家自然科学基金委员会,青年项目,81903875,黄芪甲苷通过抑制CXCR4/SDF1信号轴对抗骨关节炎的作用机制研究,2020.1-2023.1220万,在研,主持

    2.         广东省科学技术厅,省自然基金面上项目,2020A1515011342,脂肪酸结合蛋白 4FABP4)诱导软骨基质降解的机制研究,2019.10-2022.910万,在研,主持

    3.         深圳市科技创新委员会,基础研究面上项目,JCYJ20190807160601672,天然小分子 FABP4 抑制剂的发现及其对抗骨关节炎的机制研究,2020.5-2023.430万,在研,主持

    4.         佛山市中医院,登峰计划,202000189,伤科黄水治疗膝骨关节炎作用机理研究,2020.8-2022.7100万,在研,主持

    5.         NIH(美国国立卫生研究院), 项目批准号:R01 AI136982-01, Discovery and development of novel anti-HCMV agents targeting the UL89 terminase protein(发现和开发靶向 UL89 终止酶蛋白的新型抗 HCMV 药物)2019.8-2024.12300万美元,在研,参与

    6.         香港卫生署,项目批准号:12110462,艾滋病整合酶的抑制剂筛选研究,2013.4-2015.380万港币,结题,参与



  • 一、代表性论文列表

    [1] Y. Wang*, L. Chen. Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment. European Journal of Pharmacology, 889(2020): 17634

    [2] Y. Wang*, L. Chen. Lung tissue distribution of drugs as a key factor for COVID19 treatment. British Journal of Pharmacology, 177(2020): 4995-4996

    [3] Y. Wang*, C.-Y. Xiao, H.-Q. Lin, J.-S. Hu, T.-M. Ip, D.C.-C. Wan, Development of an Enzyme-Linked Immunosorbent Assay for Keap1-Nrf2 Interaction Inhibitors Identification, Redox Biology, 34(2020):101573.

    [4] F.Y. Qin, H.X. Zhang, Q.Q. Di, Y. Wang, Y.M. Yan, W.L. Chen, Y.X. Cheng. Ganoderma cochlear Metabolites as Probes to Identify a COX-2 Active Site and as in Vitro and in Vivo Anti-Inflammatory Agents. Organic Letters. 22(2020):2574-2578.

    [5] Y.M. Yan, H.X. Zhang, H. Liu, Y. Wang, J.B. Wu, Y.P. Li, Y.X. Cheng. (+/-)-Lucidumone, a COX-2 Inhibitory Caged Fungal Meroterpenoid from Ganoderma lucidum. Organic Letters, 21(2019):8523-8527.

    [6] Y. Wang, R.J. Geraghty, FRET-based assay using a three-way junction DNA substrate to identify inhibitors of human cytomegalovirus pUL89 endonuclease activity, European Journal of Pharmaceutical Sciences, 127 (2019) 29-37.

    [7] Y. Wang, J. Tang, Z. Wang, R.J. Geraghty, Metal-chelating 3-hydroxypyrimidine2, 4-diones inhibit human cytomegalovirus pUL89 endonuclease activity and virus replication, Antiviral research, 152 (2018) 10-17.

    [8] W.L. Pan, Y. Wang, Y. Hao, J.H. Wong, W.C. Chan, D.C.-C. Wan, T.B. Ng, Overexpression of CXCR4 synergizes with LL-37 in the metastasis of breast cancer cells, Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1864 (2018) 3837-3846.

    [9] J. Kankanala, Y. Wang, R.J. Geraghty, Z. Wang, Hydroxypyridonecarboxylic acids as inhibitors of human cytomegalovirus pUL89 endonuclease, ChemMedChem, 13 (2018) 1658-1663.

    [10] S. Hou, H. Xu, J. Hu, J. Hou, Y. Wang, Z. Jin, D.C. Wan, C. Hu, Synthesis, βcatenin Translocation Capability and ALP Activation Activity of 7H-thiazolo [3, 2-b]-1, 2, 4-triazin-7-one Derivatives, Medicinal Chemistry, 14 (2018) 67-73.

    [11] W. Zhou, Y. Wang, J. Xie, R.J. Geraghty, A fluorescence-based high-throughput assay to identify inhibitors of tyrosylprotein sulfotransferase activity, Biochemical and biophysical research communications, 482 (2017) 1207-1212.

    [12] Y. Wang, L. Mao, J. Kankanala, Z. Wang, R.J. Geraghty, Inhibition of human cytomegalovirus pUL89 terminase subunit blocks virus replication and genome cleavage, Journal of virology, 91 (2017) e02152-02116.

    [13] Y. Wang, H.-Q. Lin, P. Wang, J.-S. Hu, T.-M. Ip, L.-M. Yang, Y.-T. Zheng, D. Chi-Cheong Wan, Discovery of a novel HIV-1 integrase/p75 interacting inhibitor by docking screening, biochemical assay, and in vitro studies, Journal of chemical information and modeling, 57 (2017) 2336-2343.

    [14] Y. Wang, H.-Q. Lin, C.-Y. Xiao, W.-K. Law, J.-S. Hu, T.-M. Ip, D.C.-C. Wan, Using molecular docking screening for identifying hyperoside as an inhibitor of fatty acid binding protein 4 from a natural product database, Journal of functional foods, 20 (2016) 159-170.

    [15] Y. Wang, J.-S. Hu, H.-Q. Lin, T.-M. Ip, D.C.-C. Wan, Herbalog: A tool for target-based identification of herbal drug efficacy through molecular docking, Phytomedicine, 23 (2016) 1469-1474.

    [16] Y. Wang, J.H. Wong, D.T.M. Ip, D.C.C. Wan, R.C. Cheung, T.B. Ng, Bovine Lactoferrampin, Human Lactoferricin, and Lactoferrin 1-11 Inhibit Nuclear Translocation of HIV Integrase, Applied biochemistry and biotechnology, 179 (2016) 1202-1212.

    [17] T.B. Ng, R.C.F. Cheung, J.H. Wong, Y. Wang, D.T.M. Ip, D.C.C. Wan, J. Xia, Antiviral activities of whey proteins, Applied microbiology and biotechnology, 99 (2015) 6997-7008.

    [18] W.-C. Liang, W.-M. Fu, C.-W. Wong, Y. Wang, W.-M. Wang, G.-X. Hu, L. Zhang, L.-J. Xiao, D.C.-C. Wan, J.-F. Zhang, The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer, Oncotarget, 6 (2015) 22513.

    [19] W.C. Liang, Y. Wang, P.P. Liang, X.Q. Pan, W.M. Fu, V.S.Y. Yeung, Y.F. Lu, D.C.C. Wan, S.K.W. Tsui, S.Y. Tsang, MiR25 Suppresses 3T3L1 Adipogenesis by Directly Targeting KLF4 and C/EBPα, Journal of cellular biochemistry, 116 (2015)

    2658-2666.

    [20] Y. Wang, H.-Q. Lin, W.-K. Law, W.-C. Liang, J.-F. Zhang, J.-S. Hu, T.-M. Ip, M.M.-Y. Waye, D.C.-C. Wan, Pimozide, a novel fatty acid binding protein 4 inhibitor, promotes adipogenesis of 3T3-L1 cells by activating PPARγ, ACS chemical neuroscience, 6 (2014) 211-218.

    [21] Y. Wang, W.-C. Liang, W.-L. Pan, W.-K. Law, J.-S. Hu, D.T.-M. Ip, M.M.-Y. Waye, T.-B. Ng, D.C.-C. Wan, Silibinin, a novel chemokine receptor type 4 antagonist, inhibits chemokine ligand 12-induced migration in breast cancer cells, Phytomedicine, 21 (2014) 1310-1317.

    [22] Y. Wang, W.-K. Law, J.-S. Hu, H.-Q. Lin, T.-M. Ip, D.C.-C. Wan, Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening, Journal of chemical information and modeling, 54 (2014) 3046-3050.

    [23] H.-Q. Lin, Y. Wang, K.-L. Chan, T.-M. Ip, C.-C.D. Wan, Differential regulation of lipid metabolism genes in the brain of acetylcholinesterase knockout mice, Journal of Molecular Neuroscience, 53 (2014) 397-408.

    [24] W.-C. Liang, Y. Wang, L.-J. Xiao, Y.-B. Wang, W.-M. Fu, W.-M. Wang, H.-Q. Jiang, W. Qi, D.C.-C. Wan, J.-F. Zhang, Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform, RNA biology, 11 (2014) 845-854.

    [25] W.-g. Gu, D.T.-M. Ip, S.-j. Liu, J.H. Chan, Y. Wang, X. Zhang, Y.-t. Zheng, D.C.-C. Wan, 1, 4-Bis (5-(naphthalen-1-yl) thiophen-2-yl) naphthalene, a small molecule, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular Lens epithelium-derived growth factor, Chemico-biological interactions, 213 (2014) 21-27.

     

    二、授权专利

    • David CC Wan, Yan Wang, Jianshu Hu, Denis IpDiscovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening US9968616B2),发明专利,2018.05.15,美国

     

    三、获奖证明

     

    • 深圳市海外高层次人才孔雀计划” C类引进人才,2019年。

  • 更新中……

版权所有:© 转化医学研究与发展中心 备案号: 技术支持: 深圳网站建设 (佰达科技)